SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Lockmer Sandra)
 

Sökning: WFRF:(Lockmer Sandra) > Minimal residual di...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005024naa a2200481 4500
001oai:DiVA.org:liu-200753
003SwePub
008240207s2023 | |||||||||||000 ||eng|
009oai:prod.swepub.kib.ki.se:154092187
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-2007532 URI
0247 a https://doi.org/10.1002/cam4.66402 DOI
0247 a http://kipublications.ki.se/Default.aspx?queryparsed=id:1540921872 URI
040 a (SwePub)liud (SwePub)ki
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Nahi, Harethu Linköpings universitet,Institutionen för biomedicinska och kliniska vetenskaper,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US,Karolinska Inst, Sweden4 aut0 (Swepub:liu)n/a
2451 0a Minimal residual disease status is the prognostic determinant following high-dose treatment for patients with multiple myeloma
264 1b WILEY,c 2023
338 a electronic2 rdacarrier
500 a Funding Agencies|We would like to extend our gratitude to all patients and their families who participated in this study. Their willingness to contribute has been crucial for the continuation of our research. We would also like to acknowledge the invaluable work of our col
520 a Background: The presence of minimal residual disease (MRD+) following autologous stem cell transplantation (ASCT) in multiple myeloma represents a poor prognostic factor for progression-free survival (PFS) and overall survival (OS).Methods: At our department, we recommend lenalidomide maintenance for patients who are MRD+ after ASCT, while MRD-negative (MRD-) patients, after information about the national guidelines, were not advised to follow this regimen.Results: Out of the total 228 patients, 175 received ASCT following first-line induction (MRD- 92 (53%), MRD+ 83 (47%), at 2 months post-ASCT), while 53 underwent ASCT after second-line treatment (MRD- 27 (51%), MRD+ 26 (49%), at the same time point). Comparatively, MRD- patients who did not receive maintenance demonstrated better OS than MRD+ patients who received upfront ASCT and maintenance treatment (96% vs. 86%, p = 0.030, at 3 years). However, nonsignificant difference was found in PFS (76% vs. 62%, at 3 years). Furthermore, second-line ASCT, MRD- non-maintained patients exhibited significantly better PFS than MRD+ (71% vs. 27%, p > 0.001, at 3 years). However, OS was better but nonsignificant (96% vs. 76%, at 3 years). Fluorescence in situ hybridization (FISH) analysis was performed on 141 out of the 228 patients. Of these, 85 (60%) patients were deemed standard risk (SR), and 56 (40%) were classified as high risk (HR). In the SR cohort, MRD- patients exhibited better PFS and OS than MRD+ patients (71% vs. 59% and 100% vs. 85%, respectively). In the HR cohort, the MRD- patients showed superior PFS but similar OS compared to MRD+ patients (66% vs. 42% and 81% vs. 80%, respectively).Conclusions: Our results indicate that being MRD- is a more crucial prognostic factor for the 3-year PFS and OS than the presence of high-risk cytogenetic markers or undergoing maintenance treatment. The latter appears insufficient, particularly for MRD+ patients following ASCT in the second-line setting, suggesting that these patients may require a more intensive treatment approach.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a minimum residual disease; multiple myeloma prognosis
7001 a Afram, Gabrielu Karolinska Inst, Sweden4 aut
7001 a Uttervall, Katarinau Karolinska Institutet4 aut
7001 a Lockmer, Sandrau Karolinska Inst, Sweden4 aut
7001 a Tätting, Love,d 1988-u Linköpings universitet,Avdelningen för kirurgi, ortopedi och onkologi,Medicinska fakulteten,Region Östergötland, Hematologiska kliniken US4 aut0 (Swepub:liu)lovta16
7001 a Gahrton, Gostau Karolinska Inst, Sweden4 aut
7001 a Kashif, Muhammadu Karolinska Inst, Sweden; Karolinska Inst, Sweden4 aut
7001 a Alici, Evrenu Karolinska Inst, Sweden4 aut
7001 a Stromberg, Olgau Dept Med, Sweden4 aut
7001 a Klimkowska, Monikau Karolinska Institutet4 aut
7001 a Lund, Johanu Karolinska Inst, Sweden4 aut
7102 a Linköpings universitetb Institutionen för biomedicinska och kliniska vetenskaper4 org
7730 t Cancer Medicined : WILEYg 12:22, s. 20736-20744q 12:22<20736-20744x 2045-7634
8564 u https://doi.org/10.1002/cam4.6640y Fulltext
8564 u https://liu.diva-portal.org/smash/get/diva2:1835835/FULLTEXT01.pdfx primaryx Raw objecty fulltext:print
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-200753
8564 8u https://doi.org/10.1002/cam4.6640
8564 8u http://kipublications.ki.se/Default.aspx?queryparsed=id:154092187

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy